Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation

Transplant International

Volumn 23, Issue 2, 2010, Pages 231-233

  Cramer, Jakob P ^a   Lohse, Ansgar W ^a   Burchard, Gerd D ^a   Fischer, Lutz ^a   Nashan, Björn ^a   Zimmermann, Mathias ^b   Marx, Andreas ^a   Kluge, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Institut fur Medizinische Diagnostik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ETHAMBUTOL; ISONIAZID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TACROLIMUS;

ACUTE HEPATITIS; ADULT; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENETIC VARIABILITY; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; LIVER TRANSPLANTATION; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; DRUG-INDUCED LIVER INJURY; FEMALE; GENES, MDR; GENETIC VARIATION; HETEROZYGOTE; HUMANS; ISONIAZID; LIVER TRANSPLANTATION; MIDDLE AGED; MUTATION; RISK FACTORS;

EID: 73449088743     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00921.x     Document Type: Letter

References (15)

1. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006 5 : 231.
2. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006 11 : 699.
3. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf 1996 15 : 394.
4. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol 2008 23 : 192.
5. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004 10 : 1018.
6. Barcena R, Oton E, Angeles Moreno M, et al. Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis? Am J Transplant 2005 5 : 2796.
7. Idilman R, Ersoz S, Coban S, Kumbasar O, Bozkaya H. Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy. Liver Transpl 2006 12 : 1427.
8. Wu SS, Chao CS, Vargas JH, et al. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation 2007 84 : 173.
9. Higuchi N, Tahara N, Yanagihara K, et al. NAT2*6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 2007 13 : 6003.
10. Cho HJ, Koh WJ, Ryu YJ, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007 87 : 551.
11. Luca F, Bubba G, Basile M, et al. Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS ONE 2008 3 : e3136.
12. Patin E, Barreiro LB, Sabeti PC, et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet 2006 78 : 423.
13. Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006 62 : 423.
14. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005 128 : 116.
15. Sass DA, Shakil AO. Fulminant hepatic failure. Liver Transpl 2005 11 : 594.